



Published in final edited form as:

*Matrix Biol.* 2015 ; 0: 147–156. doi:10.1016/j.matbio.2015.01.004.

## Matrix metalloproteinases in liver injury, repair and fibrosis

**Sergio Duarte, John Baber, Takehiro Fujii, and Ana J. Coito**

The Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

### Abstract

The liver is a large highly vascularized organ with a central function in metabolic homeostasis, detoxification, and immunity. Due to its roles, the liver is frequently exposed to various insults which can cause cell death and hepatic dysfunction. Alternatively, the liver has a remarkable ability to self-repair and regenerate after injury. Liver injury and regeneration have both been linked to complex extracellular matrix (ECM) related pathways. While normal degradation of ECM components is an important feature of tissue repair and remodeling, irregular ECM turnover contributes to a variety of liver diseases. Matrix metalloproteinases (MMPs) are the main enzymes implicated in ECM degradation. MMPs not only remodel the ECM, but also regulate immune responses. In this review, we highlight some of the MMP-attributed roles in acute and chronic liver injury and emphasize the need for further experimentation to better understand their functions during hepatic physiological conditions and disease progression.

### Keywords

Liver; Liver injury; Acute liver injury; Liver ischemia and reperfusion injury; Chronic liver injury; Extracellular matrix; Matrix metalloproteinases

### Introduction

The liver is a vital organ, responsible for the metabolism of carbohydrates, proteins and lipids, removal of drugs and toxins from the blood, and regulation of immune responses [1]. The hepatic parenchyma is organized in lobules, which are repetitive functional units consisting of hepatocytes, endothelial cells, Kupffer cells, stellate cells, and bile duct cells [2]. Hepatocytes carry out most of the metabolic functions of the liver, and account for about 80% of the liver weight and for about 70% of all liver cells [3]. Hepatocytes, endothelial cells, as well as other liver cells, are each uniquely susceptible to a number of insults and take part in diverse clinically recognized syndromes of liver injury [4]. Alternatively, the liver has a remarkable regenerative potential as evidenced by the capability to regulate its growth and mass after hepatectomy and by its recovery after ischemic, toxic, or infectious acute liver injury [5,6]. The extracellular matrix (ECM), formed by the complex network of

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Correspondence to Ana J. Coito:** The Dumont-UCLA Transplant Center, David Geffen School of Medicine at UCLA, 77-120 CHS, Box 957054, Los Angeles, CA 90095-7054, United States, acoito@mednet.ucla.edu.

proteins and sugars surrounding cells in all solid tissues, is among the most important regulators of cellular and tissue functions in the body [7]. In addition to providing a physical scaffold and structural support for cells, ECM regulates various cellular functions, such as adhesion, migration, differentiation, proliferation, and survival. Cellular responses are context dependent, and dysregulation of ECM production and proteolysis is often associated with the development of liver pathology [8].

Matrix metalloproteinases (MMPs) are a family of over 24 zinc-dependent endopeptidases capable of degrading virtually any component of the ECM [9]. Since their initial discovery approximately 50 years ago, MMPs have emerged as essential mediators in defining how cells interact with their surrounding microenvironment [10]. MMPs have been categorized into five major groups according to their ECM substrate specificity: collagenases, gelatinases, membrane-type, stromelysins and matrilysins [11]. In addition to their recognized roles in ECM protein degradation and rearrangement, MMPs also act on non-ECM substrates, such as cytokines and chemokines, and have regulatory functions in inflammation and immunity [12]. MMPs are generally secreted into the extracellular environment, or tethered to the cell membranes, as inactive proenzymes [13]. The regulation of MMP activity is a tightly controlled process and it takes place at transcriptional, post-transcriptional, and at protein levels [14]. Dysregulation of MMP activity often results into tissue damage and functional alterations [15]. Tissue inhibitors of metalloproteinases (TIMPs) are a family of at least four identified physiological inhibitors (TIMP 1–4) capable of regulating proteolytic activities of MMPs in tissues [9,15]. TIMPs are secreted molecules that bind reversibly to MMPs in a 1:1 stoichiometric ratio. Alterations in MMP–TIMP balances have been linked to pathologies that require disruption of basement membranes, such as tumor invasion, angiogenesis, and wound healing [14,16]. However, the biology of MMPs is rather complex, since the same MMP can have opposing effects based upon the cell type or tissue in which it is expressed [17]. The choice of which MMPs to target for therapeutic purposes is still uncertain, even in fields like cancer, where MMPs have been extensively studied [18]. This article examines the role of MMPs and their TIMP natural occurring inhibitors in the development of both acute and chronic liver injury, and discusses the potential for MMP modulation in the prevention and treatment of liver diseases.

## **Extracellular matrix proteins and matrix-degrading proteases of normal liver**

ECM proteins form distinct networks with tissue-specific variation in composition and architecture [19]. These macromolecular networks surround stromal cells and underlie endothelial and epithelial cells. In a normal liver, ECM comprises less than 3% of the relative area on a tissue section, and approximately 0.5% of the wet weight. [20] Collagen, fibronectin, laminin, proteoglycans, and matricellular proteins are among the most characterized ECM components in the normal liver. Liver ECM proteins are mostly detected in the Glisson's capsule, portal tracks, central veins, and in the subendothelial space of Disse [20,21]. Collagen types I, III, IV, and V are the predominant collagens detected in the liver; collagen types I, III, and V are mostly interstitial ECM proteins in the portal and central regions, whereas collagen IV is highly detected in basement membranes [21]. Fibronectin is

abundantly expressed in the hepatic ECM; it is detected in the subcapsular connective tissue, in septa, and portal areas, and it is the main ECM component in Disse's space in normal livers [22]. The space of Disse is characterized by a low density basement membrane-like matrix, which sustains the differentiated stage of the surrounding cells and allows metabolic exchanges to take place between the blood flow and the microvilli of the hepatocytes [2,21]. Laminin similarly to collagen IV is a main component of the hepatic basement membranes [22].

ECM changes in the liver depend upon ECM synthesis and MMP-mediated ECM proteolytic degradation. Healthy adult livers have a moderate ECM turnover, which seems to correlate with the relatively small amounts of MMPs constitutively detected in those livers [23]. MMP-1, MMP-2, MMP-3, MMP-11, and MMP-13 are among the MMPs constitutively expressed in normal livers [24–27]. In addition to remodeling the ECM, MMPs can have other biological roles. MMP-2, a member of the gelatinase family which also includes MMP-9, is detected in the vascular areas of naïve livers (MMP-9 is virtually absent in naïve livers) [27]. Our unpublished studies (Kato & Coito) suggest that MMP-2 has an important role in the preservation of liver vascular homeostasis, through its participation in the TGF- $\beta$  activation process. In addition to mediating TGF- $\beta$  activation, MMP-2 is capable of modulating the activity of IL-1 $\beta$ , TNF- $\alpha$ , and MCP-3, through proteolytic cleavage [28,29]. MCP-3 is also efficiently cleaved by MMP-1 and MMP-3 [29]. MMP activity is controlled by TIMPs under physiological conditions. Low levels of TIMP-1 have been detected in the parenchyma of naïve murine livers [30]. It has been shown that exogenous TIMP-1 inhibits apoptosis of various cell types, including hepatic stellate cells and endothelial cells, which support the view that the basal expressions of TIMP-1 detected in naïve livers may contribute to the survival of liver cells [31,32]. TIMP-3 gene deletion results in spontaneous lymphocyte infiltration in naïve livers, suggesting a role in preserving liver homeostasis [33]. All together, MMPs and TIMPs seem to have important roles in the preservation of liver homeostasis. These roles should be taken into account when designing improved MMP-targeted therapies for hepatic diseases; therefore, more mechanistic studies are needed to further decipher the physiological roles of MMPs and TIMPs in the liver.

## Matrix metalloproteinases in liver injury

The liver is susceptible to various forms of injury which are frequently screened for in clinical practice. Regardless of cause, direct damage to liver cells and to their organelles can lead to the release of reactive oxygen and nitrogen (ROS, RNS) species and other pro-inflammatory mediators, which activate innate immune cells. In turn, activated Kupffer cells and infiltrating leukocytes can act to aggravate the initial liver injury [34]. A prominent feature of the hepatic response to injury is the very early appearance of newly synthesized ECM proteins, such as cellular EIIIA-fibronectin and tenascin-C [35–37]. In self-limited acute inflammation, the ECM changes are transient and the liver architecture is mostly restored, whereas in sustained injury, a persistent inflammatory response and increased accumulation of ECM progressively replace the liver parenchyma by scar fibrotic tissue [2]. Hepatic injury is frequently categorized into acute and chronic liver injury and MMPs have been linked to a number of acute and chronic liver disorders (summarized in Table 1).

## Acute liver injury

Acute liver injury is a common clinical occurrence stemming from a variety of different etiologies such as drugs, toxins, ischemia/reperfusion events, bile acids, and pathogens. Acute cellular damage mediated by oxidative stress elicits an immune response that, when uncontrolled, can lead to significant cell death [34]. If extensive cell death is not adequately balanced by liver regenerative activity, acute liver injury may progress into acute liver failure (ALF) [38]. ALF has a high mortality rate and is one of the most frequent causes for emergency orthotopic liver transplantation (OLT) [39].

In recent years, there has been considerable interest in unveiling the roles of MMPs in acute liver injury, including in settings of hepatic ischemia and reperfusion injury (IRI). Liver IRI is a prominent feature in various clinical settings that span from surgical procedures to hepatic pathologies, where blood flow to the liver is partially or completely impeded. In human liver transplantation, IRI is a major determinant of postoperative allograft dysfunction and morbidity; it also increases the risk of acute and chronic rejections [40]. Recruitment of inflammatory leukocytes is a hallmark of hepatic IR-mediated damage; however, the process of leukocyte recruitment to sites of inflammatory stimulation in the liver is still poorly understood [41]. In general, leukocytes circulate continuously in the blood, and their migration across endothelial or ECM barriers to inflamed tissues is a complex process dependent on the coordination of cellular adhesion-release steps and focal matrix degradation mechanisms. [41] The liver is a venous-driven vascular bed with slow flow rates and it may require distinct cascades of adhesive/degradation events compared with other organs with higher flow rates and different ECM profiles. Fibronectin is a large glycoprotein with a recognized central role in cellular adhesion and migration, and it is likely an important ECM protein involved in leukocyte adhesion during liver IRI [35]. The expression of cellular (EIIIA+) fibronectin by liver sinusoidal endothelial cells is an early feature after injury [37], and it precedes leukocyte recruitment in hepatic IRI [35]. Moreover, the blockade of fibronectin interactions with its most characterized  $\alpha4\beta1$  and  $\alpha5\beta1$  integrin receptors lowers leukocyte recruitment and ameliorates liver IRI in experimental organ transplantation [35,42]. Tenascin-C, similarly to cellular fibronectin, is not normally detected in adult livers, and it is likely a prominent damage-associated molecular pattern (DAMP) molecule within the ECM [43]. Tenascin-C is expressed in damage livers and its gene deletion results in reduced leukocyte recruitment and cytokine expression after hepatic reperfusion [36]. Among different MMPs, MMP-9 is emerging as an important mediator of leukocyte traffic in hepatic IRI [41]. MMP-9 is an inducible gelatinase expressed by leukocytes in acutely damaged livers [27]. MMP-9 is responsible for the turnover and degradation of several ECM proteins, including fibronectin and type IV collagen [44]. In addition to promoting ECM breakdown, MMP-9 may also increase vascular permeability by cleaving PECAM-1 and/or other endothelial junctional proteins during liver reperfusion [45]. In human orthotopic liver transplantation, MMP-9 has been detected in the serum of patients minutes after reperfusion [46], and it remained elevated for several days after transplantation [47]. In rat livers, MMP-9 has been shown by our laboratory to be upregulated after 6 h following OLT [35], and by others after 3 h of IRI [48]. MMP-9 deficiency and anti-MMP-9 antibody therapy lower the infiltration of Ly-6G

and Mac-1 leukocytes in mouse lean and steatotic livers after the IR-insult [27,45]. Further, MMP-9 inhibition has been shown to be beneficial in a model of small-for-size liver graft IRI [49]. On the other hand, TIMP-1 inhibition results in increased levels of MMP-9 activity and extensive leukocyte recruitment in severely damaged livers post-IRI [30]. MMP activity can be upregulated by nitric oxide (NO)-mediated S-nitrosylation [50]. The inhibition of nitric oxide synthase (iNOS)-derived NO production hampers MMP-9 activity as well as leukocyte recruitment in liver IRI [51].

Focal matrix degradation during leukocyte extravasation is likely regulated by a complex interplay of proteolytic cascades. MT1-MMP/MMP-14, which is expressed by infiltrating macrophages in damaged livers, facilitates their migration through FN coated membranes, suggesting that MT1-MMP/MMP-14 may act as an amplifier in the recruitment of macrophages in hepatic IRI [52]. MMP-2, MMP-3, MMP-8, MMP-10, MMP-12, and MMP-13 are among other significantly upregulated MMPs during hepatic IRI, but very little is still known about their specific functions in the progression of acute liver damage [27,48]. (Duarte & Coito, unpublished studies) MMP mediated proteolysis may not only facilitate leukocyte migration, but may also lead to detachment of parenchyma cells from ECM resulting in apoptosis, a phenomenon called “anoikis” [53]. In this regard, hepatocyte apoptosis is significantly reduced in the absence of MMP-9 after hepatic IRI [51]. Fig. 1 illustrates MMP-dependent liver damage after the IR-insult.

Drug induced acute liver injury (DILI) accounts for more than 50% of acute liver failure cases in the United States [54]. The pathological features of DILI are acute hepatocellular and endothelial cell death, cholestasis, and rapid recruitment of inflammatory leukocytes [54]. MMPs have been associated with microcirculatory dysfunctions and hepatocellular damage in acetaminophen-induced liver injury, one of the most studied models of DILI. It has been shown that treatment of livers subject to acetaminophen injury with a gelatinase inhibitor improves hepatic microcirculation and reduces the number of erythrocytes in the space of Disse [55]. In livers undergoing monocrotaline-induced acute injury, upregulation of MMP-9 correlates with the proteolysis of heparan sulfate and collagen IV and with increased neutrophil infiltration [56]. Moreover, suppression of MMP-9 activity attenuates microcirculatory obstruction in monocrotaline-induced acute liver injury [57,58]. High levels of TNF- $\alpha$  produced by macrophages is a feature of ALF [59]. Administration of batimastat (BB-94) in a murine model of TNF/GaIN induced ALF reduces leukocyte infiltration and protects livers from parenchymal apoptosis [59]. It has also been shown that MMP-8 inhibition, via reducing CXCL-5 chemokine activation, has a protective role in TNF/GaIN induced ALF [60].

In addition to hepatocyte cell death, impaired liver regeneration/repair is a common feature in acute liver failure. The balanced integration of a variety of cellular processes, such as metabolism, cell cycle regulation, angiogenesis, inflammation, cell adhesion, recruitment, and senescence, is important to assure liver regeneration [61]. While it is conceivable that ECM and MMPs can impact the majority of these processes, we are still far from understanding their roles during hepatic regeneration. Most studies in liver regeneration have been performed in murine models of partial hepatectomy; however, in humans, liver regeneration occurs most frequently after liver injury by ischemia or by other insults, such as

toxins, viral infections, and immune-mediated injuries [62]. It is important to mention that hepatectomy models do not allow the investigation of the interaction of signals coming from the inflammatory cells and their expressed growth factors and cytokines [63]. Moreover, the origin of the cells that replace missing hepatocytes differs after partial hepatectomy and parenchymal cell necrosis [64]. Hence, it is somewhat expected that MMP-dependent mechanisms of liver regeneration may vary with the nature and extent of tissue injury. MMP-9 deficient mice show a delayed regenerative response after 70% hepatectomy [65], and TIMP-1 gene deletion increases the MMP-dependent release of hepatocyte growth factor (HGF) from ECM and accelerates regeneration after major liver resection [66]. On the other hand, TIMP-1 deficiency increases the MMP-mediated shedding of c-met tyrosine kinase (cMet), the HGF receptor, in MMP-9 + leukocyte-rich livers [30], and MMP-9 gene deletion enhances the hepatocyte progression into S phase and mitosis after liver IRI [45]. Intact sinusoidal endothelial cells are necessary to stimulate the initial burst of hepatocyte proliferation [67], and therefore, it is reasonable to postulate that MMP-mediated loss of the vascular endothelial cell barrier integrity interferes with the liver's capability to regenerate after hepatic IRI [45]. Findings that physiologic doses of certain proinflammatory mediators, such as IL-6 and TNF- $\alpha$  induce liver regeneration, while their overexpressions inhibit the cell cycle progression [68], provide another example that roles and mechanisms cannot be generalized in liver regeneration. Interestingly, excessive protease activity in TIMP-3 deficient livers hampers their regeneration after hepatectomy; TIMP-3 gene deletion results in TNF- $\alpha$  increased activity and hepatocyte cell death after liver resection [69]. The mechanisms by which MMPs affect liver regeneration are likely multifactorial, and further experimentation is needed to better understand these mechanisms, particularly in clinical relevant models of liver injury.

## Chronic liver injury

Chronic liver disease is a major cause of high morbidity and mortality worldwide [2]. Chronic hepatic damage is the result of out of control wound-healing responses from the liver to various stimuli, which include viral infections, alcohol and non-alcoholic steatohepatitis (NASH) [2]. If the insult is sustained, the liver parenchyma is replaced by fibrotic scar tissue, a process in which ECM and MMPs have recognized key functions.

Chronic inflammation and repair cause an excessive accumulation of ECM components, such as fibronectin, collagens, and proteoglycans, which are major players in the formation of scar tissue. On the other hand, MMPs and TIMPs are the main regulators of ECM turnover in hepatic fibrosis [70]. The roles of MMPs and TIMPs in hepatic fibrosis have been fairly studied in the carbon tetrachloride (CCl<sub>4</sub>)-injection and the bile duct ligation (BDL) murine models [70–73]. Hepatic stellate cells, which express ECM components, MMPs and TIMPs in different timeframes are thought to play central roles in the development of hepatic fibrosis [23]. More recently, it has been suggested that hepatocyte-derived MMPs are also important mediators of ECM turnover and that the MMP-cell source is likely important in determining the final fibrotic phenotype [74]. MMP-1, MMP-8 and MMP-13 seem to be among the candidates for an anti-fibrotic role, since their overexpression has been associated to significantly reduced liver fibrosis and enhanced hepatocyte proliferation [75–77]. MMP-13 up-regulation in the liver has been correlated

with the change from normal to abnormal matrix turnover in the CCl<sub>4</sub> injury model [74]. Moreover, MMP-13 gene deletion results in a retarded resolution of CCl<sub>4</sub>-induced fibrosis [78]. However, it has also been reported that MMP-13 mediates the initial inflammation and contributes to accelerating fibrogenesis in cholestatic livers [79]. MMP-9 and MMP-12 have recently been identified in a CD11 B<sup>hi</sup> F4/80<sup>int</sup> Ly-6C<sup>lo</sup> macrophage subset associated with resolution of fibrosis [80]. MMP-9 expression has been detected in the early stages of hepatic fibrogenesis and it may release/activate TGF- $\beta$ , a major pro-fibrotic cytokine, from ECM reservoirs [81–83]. Additionally, MMP-9 may promote hepatic stellate cell apoptosis in the presence of low levels of TIMP-1 [82]. Interestingly, it has been reported that MMP-2 participates in the resolution of liver fibrosis by suppressing collagen type I expression instead of its degradation [84–86]. MMP-19 has also been linked to hepatic fibrosis; MMP-19 deficient mice show impaired TGF- $\beta$  signaling and reduced liver fibrosis in the CCl<sub>4</sub> murine model [87]. The rate and patterns of matrix degradation can be changed by the balance between TIMP and MMPs [73]. In addition to over-expressing MMPs, there is growing evidence supporting a TIMP scavenging approach to increase the ECM degrading potential in hepatic fibrosis [73]. TIMP-1 and TIMP-2 are expressed in high levels in murine fibrotic livers after CCl<sub>4</sub> administration and BDL [88]. TIMP-1 overexpression hinders the clearance of fibrotic matrix leading to extensive accumulation of interstitial ECM [89,90]. Moreover, treatment of fibrotic murine livers with modified synthetic siRNA targeting TIMP-2 reduces fibrosis by decreasing HSC activation and collagen accumulation [91]. These observations support the view that therapies aimed at overexpressing selective MMPs and reducing excessive TIMP levels may ameliorate hepatic fibrosis.

## Concluding remarks

Hepatic acute and chronic injuries are important causes of liver failure and MMPs along with their respective TIMP physiological inhibitors are promising drug-targets for these pathological conditions. MMP-9 is emerging as an important mediator of leukocyte recruitment and target in acute liver injury, whereas a TIMP scavenging approach to reduce excessive TIMP-1 or TIMP-2 expressions is solidifying as an area of interest in hepatic fibrosis. However, we must recognize that the specific roles of MMPs and TIMPs during hepatic physiological conditions and disease progression are still far from being understood. In addition to their traditional ECM remodeling functions, MMPs have the ability to process a wide range of non-ECM substrates, modifying their activity and bioavailability. Therefore, we believe that more comprehensive studies of the functions of MMPs and TIMPs are needed to provide new insights into the biology of liver damage and regeneration and to contribute in the development of more ‘tailored’ organ-based/disease-specific (OBDS) therapies against acute and chronic liver disorders.

## Acknowledgments

This work was supported in part by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) R01AI057832 grant. The authors thank Francisco William Braga for proof reading this article.

## References

1. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. *Nat Rev Immunol.* 2012; 12:201–213. [PubMed: 22362353]
2. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol.* 2011; 6:425–456. [PubMed: 21073339]
3. Si-Tayeb K, Lemaigre FP, Duncan SA. Organogenesis and development of the liver. *Dev Cell.* 2010; 18:175–189. [PubMed: 20159590]
4. Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. *Physiol Rev.* 2010; 90:1165–1194. [PubMed: 20664081]
5. Fausto N. Liver regeneration. *J Hepatol.* 2000; 32:19–31. [PubMed: 10728791]
6. Diehl AM, Chute J. Underlying potential: cellular and molecular determinants of adult liver repair. *J Clin Invest.* 2013; 123:1858–1860. [PubMed: 23635782]
7. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. *Dis Model Mech.* 2011; 4:165–178. [PubMed: 21324931]
8. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. *Hepatology.* 2000; 32:1403–1408. [PubMed: 11093750]
9. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. *Cell.* 2010; 141:52–67. [PubMed: 20371345]
10. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. *Proc Natl Acad Sci U S A.* 1962; 48:1014–1022. [PubMed: 13902219]
11. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. *Semin Cancer Biol.* 2010; 20:161–168. [PubMed: 20470890]
12. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat Rev Immunol.* 2004; 4:617–629. [PubMed: 15286728]
13. Nissinen L, Kahari VM. Matrix metalloproteinases in inflammation. *Biochim Biophys Acta.* 1840; 2014:2571–2580.
14. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. *Annu Rev Cell Dev Biol.* 2001; 17:463–516. [PubMed: 11687497]
15. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res.* 2003; 92:827–839. [PubMed: 12730128]
16. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. *Cancer Metastasis Rev.* 2006; 25:99–113. [PubMed: 16680576]
17. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. *Cancer Metastasis Rev.* 2007; 26:717–724. [PubMed: 17717634]
18. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. *Biochim Biophys Acta.* 2005; 1755:37–69. [PubMed: 15907591]
19. Schwarzbauer JE, Sechler JL. Fibronectin fibrillogenesis: a paradigm for extracellular matrix assembly. *Curr Opin Cell Biol.* 1999; 11:622–627. [PubMed: 10508649]
20. Bedossa P, Paradis V. Liver extracellular matrix in health and disease. *J Pathol.* 2003; 200:504–515. [PubMed: 12845618]
21. Martinez-Hernandez A. The hepatic extracellular matrix. I. Electron immunohistochemical studies in normal rat liver. *Lab Invest.* 1984; 51:57–74. [PubMed: 6376944]
22. Martinez-Hernandez A, Amenta PS. The extracellular matrix in hepatic regeneration. *FASEB J.* 1995; 9:1401–1410. [PubMed: 7589981]
23. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. *Semin Liver Dis.* 2001; 21:373–384. [PubMed: 11586466]
24. Moore C, Shen XD, Gao F, Busuttill RW, Coito AJ. Fibronectin- $\alpha$ 4 $\beta$ 1 integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury. *Am J Pathol.* 2007; 170:567–577. [PubMed: 17255325]




25. Lichtinghagen R, Helmbrecht T, Arndt B, Boker KH. Expression pattern of matrix metalloproteinases in human liver. *Eur J Clin Chem Clin Biochem*. 1995; 33:65–71. [PubMed: 7632822]
26. Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, et al. Differential expression of matrix- metalloproteinase-1 and -2 genes in normal and fibrotic human liver. *Am J Pathol*. 1994; 144:528–537. [PubMed: 8129038]
27. Hamada T, Fondevila C, Busuttil RW, Coito AJ. Metallo-proteinase-9 deficiency protects against hepatic ischemia/ reperfusion injury. *Hepatology*. 2008; 47:186–198. [PubMed: 17880014]
28. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. *Genes Dev*. 2000; 14:2123–2133. [PubMed: 10970876]
29. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. *Blood*. 2002; 100:1160–1167. [PubMed: 12149192]
30. Duarte S, Hamada T, Kuriyama N, Busuttil RW, Coito AJ. TIMP-1 deficiency leads to lethal partial hepatic ischemia and reperfusion injury. *Hepatology*. 2012; 56:1074–1085. [PubMed: 22407827]
31. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. *J Biol Chem*. 2002; 277:11069–11076. [PubMed: 11796725]
32. Boulday G, Fitau J, Coupel S, Soullillou JP, Charreau B. Exogenous tissue inhibitor of metalloproteinase-1 promotes endothelial cell survival through activation of the phosphatidylinositol 3-kinase/Akt pathway. *Ann N Y Acad Sci*. 2004; 1030:28–36. [PubMed: 15659777]
33. Murthy A, Shao YW, Defamie V, Wedeles C, Smookler D, Khokha R. Stromal TIMP3 regulates liver lymphocyte populations and provides protection against Th1 T cell-driven autoimmune hepatitis. *J Immunol*. 2012; 188:2876–2883. [PubMed: 22323541]
34. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. *J Gastroenterol Hepatol*. 2011; 26(Suppl. 1):173–179. [PubMed: 21199529]
35. Amersi F, Shen XD, Moore C, Melinek J, Busuttil RW, Kupiec-Weglinski JW, et al. Fibronectin-alpha 4 beta 1 integrin-mediated blockade protects genetically fat Zucker rat livers from ischemia/ reperfusion injury. *Am J Pathol*. 2003; 162:1229–1239. [PubMed: 12651615]
36. Kuriyama N, Duarte S, Hamada T, Busuttil RW, Coito AJ. Tenascin-C: a novel mediator of hepatic ischemia and reperfusion injury. *Hepatology*. 2011; 54:2125–2136. [PubMed: 21898491]
37. Jarnagin WR, Rockey DC, Kotliansky VE, Wang SS, Bissell DM. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. *J Cell Biol*. 1994; 127:2037–2048. [PubMed: 7806580]
38. Riordan SM, Williams R. Mechanisms of hepatocyte injury, multiorgan failure, and prognostic criteria in acute liver failure. *Semin Liver Dis*. 2003; 23:203–215. [PubMed: 14523674]
39. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. *Lancet*. 2010; 376:190–201. [PubMed: 20638564]
40. Henderson JM. Liver transplantation and rejection: an overview. *Hepatogastroenterology*. 1999; 46(Suppl. 2):1482–1484. [PubMed: 10431709]
41. Coito AJ. Leukocyte transmigration across endothelial and extracellular matrix protein barriers in liver ischemia/reperfusion injury. *Curr Opin Organ Transplant*. 2011; 16:34–40. [PubMed: 21150609]
42. Fondevila C, Shen XD, Duarte S, Busuttil RW, Coito AJ. Cytoprotective effects of a cyclic RGD peptide in steatotic liver cold ischemia and reperfusion injury. *Am J Transplant*. 2009; 9:2240–2250. [PubMed: 19681824]
43. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. *Nat Med*. 2009; 15:774–780. [PubMed: 19561617]

44. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. *J Clin Immunol.* 2006; 26:299–307. [PubMed: 16652230]
45. Kato H, Kuriyama N, Duarte S, Clavien PA, Busuttill RW, Coito AJ. MMP-9 deficiency shelters endothelial PECAM-1 expression and enhances regeneration of steatotic livers after ischemia and reperfusion injury. *J Hepatol.* 2014; 60:1032–1039. [PubMed: 24412604]
46. Kuyvenhoven JP, Verspaget HW, Gao Q, Ringers J, Smit VT, Lamers CB, et al. Assessment of serum matrix metalloproteinases MMP-2 and MMP-9 after human liver transplantation: increased serum MMP-9 level in acute rejection. *Transplantation.* 2004; 77:1646–1652. [PubMed: 15201662]
47. Kuyvenhoven JP, Ringers J, Verspaget HW, Lamers CB, van Hoek B. Serum matrix metalloproteinase MMP-2 and MMP-9 in the late phase of ischemia and reperfusion injury in human orthotopic liver transplantation. *Transplant Proc.* 2003; 35:2967–2969. [PubMed: 14697951]
48. Cursio R, Mari B, Louis K, Rostagno P, Saint-Paul MC, Giudicelli J, et al. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. *FASEB J.* 2002; 16:93–95. [PubMed: 11709491]
49. Ma ZY, Qian JM, Rui XH, Wang FR, Wang QW, Cui YY, et al. Inhibition of matrix metalloproteinase-9 attenuates acute small-for-size liver graft injury in rats. *Am J Transplant.* 2010; 10:784–795. [PubMed: 20121733]
50. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. *Science.* 2002; 297:1186–1190. [PubMed: 12183632]
51. Hamada T, Duarte S, Tsuchihashi S, Busuttill RW, Coito AJ. Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. *Am J Pathol.* 2009; 174:2265–2277. [PubMed: 19443702]
52. Duarte S, Shen XD, Fondevila C, Busuttill RW, Coito AJ. Fibronectin-alpha4beta1 interactions in hepatic cold ischemia and reperfusion injury: regulation of MMP-9 and MT1-MMP via the p38 MAPK pathway. *Am J Transplant.* 2012; 12:2689–2699. [PubMed: 22812390]
53. Frisch SM, Sreaton RA. Anoikis mechanisms. *Curr Opin Cell Biol.* 2001; 13:555–562. [PubMed: 11544023]
54. Lee WM. Acute liver failure. *Semin Respir Crit Care Med.* 2012; 33:36–45. [PubMed: 22447259]
55. Ito Y, Abril ER, Bethea NW, McCuskey RS. Inhibition of matrix metalloproteinases minimizes hepatic microvascular injury in response to acetaminophen in mice. *Toxicol Sci.* 2005; 83:190–196. [PubMed: 15456921]
56. Hanumegowda UM, Copple BL, Shibuya M, Malle E, Ganey PE, Roth RA. Basement membrane and matrix metalloproteinases in monocrotaline-induced liver injury. *Toxicol Sci.* 2003; 76:237–246. [PubMed: 12970574]
57. Periasamy S, Hsu DZ, Chen SY, Yang SS, Chandrasekaran VR, Liu MY. Therapeutic sesamol attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats by inhibiting matrix metalloproteinase-9. *Cell Biochem Biophys.* 2011; 61:327–336. [PubMed: 21681587]
58. Nakamura K, Hatano E, Narita M, Miyagawa-Hayashino A, Koyama Y, Nagata H, et al. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9. *J Hepatol.* 2012; 57:1037–1043. [PubMed: 22796153]
59. Wielockx B, Lannoy K, Shapiro SD, Itoh T, Itohara S, Vandekerckhove J, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. *Nat Med.* 2001; 7:1202–1208. [PubMed: 11689884]
60. Van Lint P, Wielockx B, Puimege L, Noel A, Lopez-Otin C, Libert C. Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. *J Immunol.* 2005; 175:7642–7649. [PubMed: 16301674]
61. Riehle KJ, Dan YY, Campbell JS, Fausto N. New concepts in liver regeneration. *J Gastroenterol Hepatol.* 2011; 26(Suppl. 1):203–212. [PubMed: 21199532]
62. Taub R. Liver regeneration: from myth to mechanism. *Nat Rev Mol Cell Biol.* 2004; 5:836–847. [PubMed: 15459664]

63. Michalopoulos GK. Principles of liver regeneration and growth homeostasis. *Compr Physiol*. 2013; 3:485–513. [PubMed: 23720294]
64. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. *Hepatology*. 2006; 43:S45–S53. [PubMed: 16447274]
65. Olle EW, Ren X, McClintock SD, Warner RL, Deogracias MP, Johnson KJ, et al. Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice. *Hepatology*. 2006; 44:540–549. [PubMed: 16941692]
66. Mohammed FF, Pennington CJ, Kassiri Z, Rubin JS, Soloway PD, Ruther U, et al. MetalloproteinaseinhibitorTIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. *Hepatology*. 2005; 41:857–867. [PubMed: 15726641]
67. Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. *Nature*. 2010; 468:310–315. [PubMed: 21068842]
68. Wustefeld T, Rakemann T, Kubicka S, Manns MP, Trautwein C. Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. *Hepatology*. 2000; 32:514–522. [PubMed: 10960443]
69. Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, Sanchez OH, et al. Abnormal TNF activity in *Timp3*<sup>-/-</sup> mice leads to chronic hepatic inflammation and failure of liver regeneration. *Nat Genet*. 2004; 36:969–977. [PubMed: 15322543]
70. Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. *J Gastroenterol Hepatol*. 2006; 21(Suppl. 3):S88–S91. [PubMed: 16958682]
71. Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. *Dis Model Mech*. 2014; 7:193–203. [PubMed: 24713275]
72. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs andTIMPs in liverfibrosis — a systematic review with special emphasis on anti-fibrotic strategies. *J Hepatol*. 2007; 46:955–975. [PubMed: 17383048]
73. Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. *Biochim Biophys Acta*. 1832; 2013:876–883.
74. Calabro SR, Maczurek AE, Morgan AJ, Tu T, Wen VW, Yee C, et al. Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. *PLoS One*. 2014; 9:e90571. [PubMed: 25076423]
75. Harty MW, Huddleston HM, Papa EF, Puthawala T, Tracy AP, Ramm GA, et al. Repair after cholestatic liver injury correlates with neutrophil infiltration and matrix metallo-proteinase 8 activity. *Surgery*. 2005; 138:313–320. [PubMed: 16153442]
76. Iimuro Y, Nishio T, Morimoto T, Nitta T, Stefanovic B, Choi SK, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. *Gastroenterology*. 2003; 124:445–458. [PubMed: 12557150]
77. Endo H, Niioka M, Sugioka Y, Itoh J, Kameyama K, Okazaki I, et al. Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats. *Pathobiology*. 2011; 78:239–252. [PubMed: 21849805]
78. Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. *J Immunol*. 2007; 178:5288–5295. [PubMed: 17404313]
79. Uchinami H, Seki E, Brenner DA, D'Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. *Hepatology*. 2006; 44:420–429. [PubMed: 16871591]
80. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. *Proc Natl Acad Sci U S A*. 2012; 109:E3186–E3195. [PubMed: 23100531]
81. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. *Histochem Cell Biol*. 2000; 113:443–453. [PubMed: 10933221]
82. Ramachandran P, Iredale JP. Liver fibrosis: a bidirectional model of fibrogenesis and resolution. *QJM*. 2012; 105:813–817. [PubMed: 22647759]

83. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. *Genes Dev.* 2000; 14:163–176. [PubMed: 10652271]
84. Radbill BD, Gupta R, Ramirez MC, DiFeo A, Martignetti JA, Alvarez CE, et al. Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. *Dig Dis Sci.* 2011; 56:406–416. [PubMed: 20563750]
85. Onozuka I, Kakinuma S, Kamiya A, Miyoshi M, Sakamoto N, Kiyohashi K, et al. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. *Biochem Biophys Res Commun.* 2011; 406:134–140. [PubMed: 21300023]
86. Hartland SN, Murphy F, Aucott RL, Abergel A, Zhou X, Waung J, et al. Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin. *Liver Int.* 2009; 29:966–978. [PubMed: 19580633]
87. Jirouskova M, Zbodakova O, Gregor M, Chalupsky K, Samova L, Hajduch M, et al. Hepatoprotective effect of MMP-19 deficiency in a mouse model of chronic liver fibrosis. *PLoS One.* 2012; 7:e46271. [PubMed: 23056273]
88. Roeb E, Purucker E, Breuer B, Nguyen H, Heinrich PC, Rose-John S, et al. TIMP expression in toxic and cholestatic liver injury in rat. *J Hepatol.* 1997; 27:535–544. [PubMed: 9314132]
89. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. *Hepatology.* 2002; 36:850–860. [PubMed: 12297832]
90. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. *Hepatology.* 2000; 32:1248–1254. [PubMed: 11093731]
91. Hu YB, Li DG, Lu HM. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. *J Gene Med.* 2007; 9:217–229. [PubMed: 17351970]
92. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. *Hepatology.* 1997; 26:1521–1529. [PubMed: 9397993]
93. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Immunocyto-chemical detection of MMP-3 and -10 expressions in hepatocellular carcinomas. *Anticancer Res.* 2000; 20:4585–4590. [PubMed: 11210857]
94. Huang CC, Chuang JH, Chou MH, Wu CL, Chen CM, Wang CC, et al. Matrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. *Mod Pathol.* 2005; 18:941–950. [PubMed: 15696117]
95. Zeng ZS, Shu WP, Cohen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. *Clin Cancer Res.* 2002; 8:144–148. [PubMed: 11801551]
96. Siller-Lopez F, Sandoval A, Salgado S, Salazar A, Bueno M, Garcia J, et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. *Gastroenterology.* 2004; 126:1122–1133. [discussion 949]. [PubMed: 15057751]
97. Kato H, Kuriyama N, Duarte S, Clavien PA, Busuttill RW, Coito AJ. MMP-9 deficiency shelters endothelial PECAM-1 expression and enhances regeneration of steatotic livers after ischemia and reperfusion injury. *J Hepatol.* 2014; 60:1032–1039. [PubMed: 24412604]
98. Nguyen JH, Yamamoto S, Steers J, Sevlever D, Lin W, Shimojima N, et al. Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. *J Hepatol.* 2006; 44:1105–1114. [PubMed: 16458990]
99. Hori T, Uemoto S, Walden LB, Chen F, Baine AM, Hata T, et al. Matrix metalloproteinase-9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: a pilot study in mice. *Hepatol Res.* 2014; 44:651–662. [PubMed: 23672352]
100. Zhou X, Murphy FR, Gehdu N, Zhang J, Iredale JP, Benyon RC. Engagement of alpha5beta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. *J Biol Chem.* 2004; 279:23996–24006. [PubMed: 15044441]

101. Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. *Hepatology*. 1996; 24:316–322. [PubMed: 8690399]
102. Sakamoto Y, Mafune K, Mori M, Shiraishi T, Imamura H, Mori M, et al. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. *Int J Oncol*. 2000; 17:237–243. [PubMed: 10891530]
103. Sun MH, Han XC, Jia MK, Jiang WD, Wang M, Zhang H, et al. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. *World J Gastroenterol*. 2005; 11:5931–5937. [PubMed: 16273602]
104. Nart D, Yaman B, Yilmaz F, Zeytunlu M, Karasu Z, Kilic M. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. *Liver Transpl*. 2010; 16:621–630. [PubMed: 20440771]
105. Garcia-Irigoyen O, Carotti S, Latasa MU, Uriarte I, Fernandez-Barrena MG, Elizalde M, et al. Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. *Liver Int*. 2014; 34:e257–e270. [PubMed: 24119197]
106. Pellicoro A, Aucott RL, Ramachandran P, Robson AJ, Fallowfield JA, Snowdon VK, et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloproteinase (MMP-12) during experimental liverfibrosis. *Hepatology*. 2012; 55:1965–1975. [PubMed: 22223197]
107. Madala SK, Pesce JT, Ramalingam TR, Wilson MS, Minnicozzi S, Cheever AW, et al. Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. *J Immunol*. 2010; 184:3955–3963. [PubMed: 20181883]
108. Yata Y, Takahara T, Furui K, Zhang LP, Watanabe A. Expression of matrix metalloproteinase-13 and tissue inhibitor of metalloproteinase-1 in acute liver injury. *J Hepatol*. 1999; 30:419–424. [PubMed: 10190724]
109. Hironaka K, Sakaida I, Matsumura Y, Kaino S, Miyamoto K, Okita K. Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis. *Biochem Biophys Res Commun*. 2000; 267:290–295. [PubMed: 10623612]
110. Harada T, Arii S, Mise M, Imamura T, Higashitsuji H, Furutani M, et al. Membrane-type matrix metalloproteinase-1 (MT1-MTP) gene is overexpressed in highly invasive hepatocellular carcinomas. *J Hepatol*. 1998; 28:231–239. [PubMed: 9514536]
111. Zhou X, Hovell CJ, Pawley S, Hutchings MI, Arthur MJ, Iredale JP, et al. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liverfibrosis and might contribute to fibrolysis. *Liver Int*. 2004; 24:492–501. [PubMed: 15482348]
112. Arai I, Nagano H, Kondo M, Yamamoto H, Hiraoka N, Sugita Y, et al. Overexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasion. *Hepatogastroenterology*. 2007; 54:167–171. [PubMed: 17419254]



**Fig. 1.** Schematic model for MMP-dependent liver damage after the IR-insult. The IR-insult to the liver results in MMP-dependent and independent release of ROS, cytokines, and other pro-inflammatory mediators, which activate innate immune cells and upregulate the expression of liver vascular adhesion molecules. Interactions between activated integrins (e.g.  $\alpha 4\beta 1$  and  $\alpha 5\beta 1$ ) expressed on leukocytes and newly synthesized adhesion molecules promote binding of leukocytes to the liver endothelium. MMPs, particularly leukocyte-derived MMP-9 (in the presence of low levels of TIMP-1), facilitate focal matrix degradation and leukocyte extravasation across vascular barriers. Besides leukocyte recruitment, MMP-mediated loss of the vascular endothelial cell barrier integrity interferes with the liver's capability to regenerate after hepatic IRI. Additionally, MMPs contribute to tissue injury by promoting parenchyma cell detachment from ECM, resulting in apoptosis/anoikis of parenchyma cells. Pro-inflammatory factors produced during the acute phase of IRI, such as TNF- $\alpha$ , and iNOS-derived NO, further stimulate the production/activation of MMPs, which in turn modulate the activity of some of these factors through proteolytic cleavage; thus, providing a possible feedback loop that would amplify and sustain the inflammatory environment.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 1**

## Matrix metalloproteinases in liver injury.

<b>Matrix Metalloproteinase</b>	<b>Liver pathology</b>
MMP-1 (collagenase-1)	<ul style="list-style-type: none"> <li>• ECM degradation in hepatic fibrosis [76].</li> </ul>
MMP-2 (gelatinase-A)	<ul style="list-style-type: none"> <li>• Expressed in liver IRI [24,27].</li> <li>• Preserved vascular homeostasis in liver IRI. [Kato &amp; Coito, unpublished studies]</li> <li>• Expressed in human fibrotic livers [92].</li> <li>• Absence exacerbated liver fibrosis [85].</li> <li>• Suppressed collagen type I expression [84].</li> </ul>
MMP-3 (stromelysin-1)	<ul style="list-style-type: none"> <li>• Expressed in normothermic ischemia injury [48].</li> <li>• Expressed in hepatocellular carcinoma [93].</li> </ul>
MMP-7 (matrilysin-1)	<ul style="list-style-type: none"> <li>• Upregulated in liver IRI. [Baber &amp; Coito, unpublished studies]</li> <li>• Expressed in biliary atresia fibrosis [94].</li> <li>• Associated to colorectal carcinoma liver metastasis [95].</li> </ul>
MMP-8 (collagenase-2)	<ul style="list-style-type: none"> <li>• Upregulated in liver IRI. [Duarte &amp; Coito, unpublished studies]</li> <li>• Overexpression reduced fibrosis [96].</li> <li>• Expressed in cholestatic injury [75].</li> <li>• Promoted leukocyte infiltration in TNF-induced acute hepatitis [60].</li> </ul>
MMP-9 (gelatinase-B)	<ul style="list-style-type: none"> <li>• Expressed by leukocytes in liver IRI [24].</li> <li>• Expressed in normothermic ischemia injury [48].</li> <li>• Mediated leukocyte infiltration in liver IRI [27].</li> <li>• Promoted PECAM-1 proteolytic breakdown in liver IRI [97].</li> <li>• Hepatocyte apoptosis in liver IRI [51].</li> <li>• Activated myeloperoxidase in liver IRI [27].</li> <li>• Impaired liver regeneration after liver IRI [97].</li> <li>• Favored hepatic regeneration after hepatectomy [65].</li> <li>• Mediated acute small-for-size graft injury [49].</li> <li>• Facilitated brain extravasation and edema in fulminant hepatic failure [98,99].</li> <li>• Promoted hepatic stellate cell apoptosis [100].</li> <li>• Expressed in hepatocellular carcinoma [101–104].</li> <li>• Associated to neutrophil infiltration in monocrotaline-induced acute liver injury [56].</li> </ul>
MMP-10 (stromelysin-2)	<ul style="list-style-type: none"> <li>• Upregulated in liver IRI. [Duarte &amp; Coito, unpublished studies]</li> <li>• Promoted hepatic repair and regeneration after partial hepatectomy and bile duct ligation [105].</li> <li>• Expressed in hepatocellular carcinoma [93].</li> </ul>
MMP-11 (stromelysin-3)	<ul style="list-style-type: none"> <li>• Expressed in normothermic ischemia injury [48].</li> </ul>
MMP-12 (matrilysin-2)	<ul style="list-style-type: none"> <li>• Expressed in normothermic ischemia injury [48].</li> <li>• Degraded elastin in hepatic fibrosis [106].</li> <li>• Promoted inflammation and IL-13 induced hepatic fibrosis [107].</li> </ul>
MMP-13 (collagenase-3)	<ul style="list-style-type: none"> <li>• Expressed in acute liver injury [108].</li> <li>• Accelerated liver fibrogenesis [79].</li> <li>• Promoted recovery from liver fibrosis [77,78,109].</li> </ul>
MMP-14 (MT1-MMP)	<ul style="list-style-type: none"> <li>• Associated to liver recruitment in liver IRI [52].</li> </ul>

Matrix Metalloproteinase	Liver pathology
	<ul style="list-style-type: none"><li>• Upregulated after partial hepatectomy [66].</li><li>• Expressed in highly invasive hepatocellular carcinoma [110].</li><li>• Expressed in liver fibrosis and linked to its resolution [92,111].</li></ul>
MMP-15(MT2-MMP)	<ul style="list-style-type: none"><li>• Downregulated after partial hepatectomy [66].</li></ul>
MMP-16(MT3-MMP)	<ul style="list-style-type: none"><li>• Expressed in hepatitis [112].</li><li>• Expressed in cirrhosis and hepatocellular carcinoma [112].</li></ul>
MMP-19 (enamelysin)	<ul style="list-style-type: none"><li>• Promoted TGF-<math>\beta</math> signaling in development of liver fibrosis [87].</li></ul>
MMP-24 (MT5-MMP)	<ul style="list-style-type: none"><li>• Expressed after partial hepatectomy [66].</li></ul>

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript